Cystic Fibrosis Foundation Therapeutics, Inc. and Pulmatrix Initiate Collaboration to Accelerate PUR118 in the Treatment of Cystic Fibrosis
9/14/2012 9:05:27 AM
More...
|
Quotient and Pulmatrix Announce Completion of Innovative COPD Proof-of-Concept Clinical Program
9/4/2012 12:41:21 PM
More...
|
Pulmatrix Taps Robert Clarke, Ph.D. CEO, Releases Promising Data on Lung Drug
9/4/2012 7:34:14 AM
More...
|
Pulmatrix Announces Presentations at European Respiratory Society Annual Congress for Lead Inhaled iCALM Drug Candidate, PUR118
8/27/2012 10:13:24 AM
More...
|
Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled Therapeutic Reduced Airway Inflammation
5/22/2012 10:58:17 AM
More...
|
Pulmatrix Announces Presentations at ATS 2012 International Conference
5/16/2012 10:15:11 AM
More...
|
Pulmatrix Demonstrates iSPERSE Capabilities for Inhaled Dry Powder Delivery of Antibiotics and Antibodies
5/15/2012 10:14:13 AM
More...
|
Pulmatrix Announces Grant of Patent Supporting Its Novel Pulmonary Drug Therapies
1/5/2012 5:59:04 AM
More...
|
Pulmatrix Presents Data on iSPERSE for Inhaled Combination Drug Therapies, Including Triple Drug Combinations
12/19/2011 6:05:58 AM
More...
|
Pulmatrix Demonstrates Superiority of in Delivering An Effective Multi-Drug Inhaled Dose Compared to Conventional Formulation
10/31/2011 6:38:46 AM
More...
|
|